CC Community News Digest (November 9-15)

Assorted news from the last week:

CAC2 Member Joe Baber urges community members to take immediate action to secure Senate passage of the Creating Hope Reauthorization Act, in this guest blog post.  “Because of the incentives in this bill, for the first time, we now have several kids’ cancer drugs in development,” Joe writes. “We cannot allow this bill to die on the Senate floor! The House passed a version of this bill on September 30, but so far, only two of our 100 Senators have cosponsored the Senate version. It will die if it doesn’t pass by December 11.”  Also contains specific action steps you can take today to help keep the Creating Hope Act alive.

A study out of US-Davis has found that adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment. The most common complications were cardiovascular, endocrine and respiratory diseases and presented more commonly among non-white AYA patients and those living in more deprived neighborhoods.

For some children with the rare eye cancer retinoblastoma, results from a study in mice suggest that CAR T-cell therapy could be an effective treatment.

Is proton therapy the silver bullet for children with brain cancer?

Collaboration at work:  thanks to a funding partnership among childhood cancer foundations, pediatric cancer researchers at Children’s Hospital Philadelphia and Gustav Roussy received $1.3 Million to study precise treatment for neuroblastoma.

Upcoming Webinars and Online Opportunities:

Please register to attend the  9th ACCELERATE Paediatric Oncology Conference, 4-5 February 2021 (EU afternoons, US mornings).  The annual ACCELERATE Conference aims to strengthen international cooperation between academia, parent groups, biopharma companies, regulatory bodies and HTA bodies to improve and speed up the global development of new paediatric oncology drugs.  Please consider attending to:
  • LEARN from recent successes in paediatric oncology drug development worldwide;
  • HEAR about the latest regulatory updates in Europe and America;
  • DISCUSS in breakout sessions how to accelerate implementation new oncology drug development for children in this new global landscape;
  • SHARE advancements in the ACCELERATE program: Paediatric Strategy Forums and Working Groups (FAIR Trials, International Collaboration, Long Term Follow-Up Needs, Fit For Filing) and what is in the pipeline; and
  • STRENGTHEN multi-stakeholder international collaboration.
The inaugural Neuroblastoma Parent Global Symposium was held on November 6th and 7th, 2020.  Sessions featured information on current treatments around the world and share emerging therapies.  This information is available to view (free registration may be required).

CAC2 hosted leaders of the New Approaches to Neuroblastoma Therapy (NANT) consortium about the progress and challenges associated with developing new strategies for refractory and relapsed neuroblastoma patients  Click the link to view the presentation and learn about the history of this 20 year-old, multi-institution network, their collaborations with the Children’s Oncology Group and other partners, current clinical trials and plans for future studies.

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.